Deneysel olarak fibrosarkoma oluşturulan ratların serumlarında İnterlökin 6(IL-6) ve Tümör nekrosis faktör-∝ (TNF-∝) düzeylerinin belirlenmesi

Sitokinler vücutta değişik hücreler tarafından sentezlenen, multi fonksiyonel polipeptitlerdir. Sitokinlerden biri olan TNF-∝ doğal ve kazanılmış bağışıklık, hücre regülasyonu, farklılaşması ve apoptosis süreçlerinde önemli rollere sahip; IL-6 ise doğal ve kazanılmış bağışıklık, karsinoma ve B hücresiz leukemilerde çoğalmayı önleyici, değişik dokuların büyümesini, farklılaşmasını düzenleyen bir çok işlevi olan sitokinlerdir. Çalışmada ratlarda deneysel olarak 3-metilkolantren ile oluşturulan fibrosarkomlarda, IL-6 ve TNF-∝ düzeyleri belirlendi. Araştırmanın materyalini 16 adet 8 haftalık ağırlıkları 150-200 gram olan erkek Spraque Dawley türü rat oluşturdu. Deneme süresinin başında deneme grubundaki ratların boyun bölgelerinin dorsaline, fibrosarkoma oluşturmak üzere 0.25 ml susam yağında çözdürülen 0.2 mg 3-metilkolantren, kontrol grubuna ise tek doz 0.25 ml susam yağı deri altı yolla tek doz enjekte edildi. Tümor oluşumu yaklaşık 150-210 gün sürdü. Deney süresinin sonunda ratlara eter anestezisi altında ötenazi uygulanarak kalbin atrium kısmından alınan kanlar santrifüj edilerek serumları ayrıldı. Serumlarda IL-6 ve TNF-∝ düzeylerine, ELISA yöntemiyle BioSource firmasının kitleriyle bakıldı. Deneme grubundaki ratlarda serum IL-6 düzeyleri ortalama 67.85±3.13 pg/ml, kontrol grubunda ise 38.45±3.39 pg/ml; TNF-∝ düzeyleri ise deneme grubunda ortalama 53.35±9.08 pg/ml, kontrol grubunda ise 26.42±2.22 pg/ml olarak tespit edildi, deneme grubundaki serum IL-6 düzeyinin kontrol grubuna göre 1.8 kat; serum TNF-∝ düzeylerinin 2 kat arttığı belirlendi. Elde edilen bulgular sonucunda, çalışma sonuçlarının, kanserin patognezinin aydınlatılması ve prognozu alanında yapılacak çalışmalara katkıda bulunacağı, kanısına varılmıştır.

Anahtar Kelimeler:

tümör nekroz faktör, sıçan, prognoz, patojenez, neoplazma, interlökin 6, sitokin, ELISA

Levels of interleukin 6 and tumor necrosis factor-∝ in serum from fibrosarcoma induced rats

Cytocines, produced by virtually all types of cells, are multifunctional polypeptide. TNF-∝ is a plethoric cytokine that has a major role in natural and acquired immune, cell regulation and differentiation and apoptosis. IL-6 has a lot of functions in natural and acquired immune, inhibit growth at carcinoma, tissue’s growthing and differential. In this study, serum IL-6 and TNF-∝ levels were investigated in fibrosarcoma induced by 3-methylcholantrene. Sixteen male Spraque Dawley rats were used in this study. The experiment took about 150-210 days until the appearance of tumor tissue. 0.2mg 3-methylcholantrene solved in 0.25ml sesame oil were injected subcutaneously on the neck to experimental group, however only sesame oil given to control group. To find out whether any tumor tissue occurred animals were palpated daily. At the end of the experiment, the blood of animals was taken from atrium of the hearth under the ether anesthesia and than serum was prepared. Serum IL-6 and TNF-∝ levels were analyzed using BioSource kits at ELISA. Serum IL-6 levels were found 67.85±3.13 pg/ml in experimental group; 38.45±3.39 pg/ml in control group. It was 1.8 times higher than controls. Serum TNF-∝ levels were 53.35±9.08 pg/ml in experimental group; 26.42±2.22 pg/ml in control group. It was 2 times higher than controls. In the light of these findings it is thought that results of study are beneficial to understand pathogenesis and prognosis of cancer.

Keywords:

tumour necrosis factor, rats, prognosis, pathogenesis, neoplasms, interleukin 6, cytokines, ELISA,

PDF

___

1.Erer H, Kıran MM: Veteriner Onkoloji. 2. Baskı, Konya, s. 76-77, 2000.
2.Wöhrmann T, Teredesai A: Metastasizing fibrosarcoma in a wistar rat. J Vet Med A, 49, 538-540, 2002.
3.Hazıroğlu R, Milli ÜH: Veteriner Patoloji. 2. Cilt, 2. Baskı, Mesipres Yayıncılık, Ankara, s: 564, 2001
4.Öztürk C: Sitokinler. Mersin Üniv Tıp Fak Derg, 2 (4): 523528, 2001.
5.Akkoç A: Proinflamatuvar ve Antiinflamatuvar Sitokinler. http//www.veteriner.uludağ.edu.tr., Erişim tarihi: 27/10/2005.
6.Çömez Yİ: Prostat adenokanseri tanısı ile takip edilen hastalarda TNF-alfa-308 A/G polimorfizim siklığının belirlenmesi ve belirli parametreler ile ilişkisinin belirlenmesi. Uzmanlık Tezi, Sağlık Bakanlığı Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi 1. Üroloji Kliniği, İstanbul, 2006.
7.Abbas AK, Lichtman HA, Pober JS: Celluler and Moleculer Immunology. 4th ed. Philadelphia, PA: W.B. Saunders, 235269, 2000.
8.Arda M, Minbay A, Aydın N, Akay Ö, İzgür M, Diker KS: Immunoloji. Medison Yayınevi, 179-192, Ankara, 1994.
9.Yeğin O: B ve T hücre reseptörleri interlökin 6. Temel İmmunoloji Notları, Akdeniz Üniversitesi, 41, 25-46, 1990.
10.Sawick B, Kasqacka L, Chyczewski L, Sobolewski K: Preliminary evaluation of mast cells in rats with an experimental fibrosarcoma induced by methylcholanthrene. Folia Histochem Cytobiol, 39 (Suppl 2): 96-97, 2001.
11.Smyth MJ, Crowe NY, Godfrey DI: NK cells and NKT cells collobrate in host protection from methylcholanthreneinduced fibrosarcoma. Int Immunol Apr, 13 (4): 459-463, 2001.
12.Van der Zee AGJ, de Cuyper EMJ, Limburg PC, de Bruijn HWA, Hollema H, Bijzet J, Krans M, de Vries GE: Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer, 75, 1004-1009, 1995.
13.Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O: Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res, 50, 6959-6965, 1990.
14. Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y: Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human carcinoma. Anticancer Res, 17, 337-342, 1997.
15.Moradi MM, Carson LF, Weinberg JB, Haney AF, Twiggs LB, Ramakrishnan S: Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer, 72, 24332440, 1993.
16.Scambia G, Testa U, Benedetti P, Martucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C, Mancuso S: Interleukin 6 serum levels in patients with gynecological tumors. Int J Cancer, 57, 318-323, 1994.
17.Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C: Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol, 66, 27-30, 1997.
18.Nilsson BM, Langley RR, Fidler IJ: Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res, 65 (23): 10794-10800, 2005.
19.Nash MA, Fernandina G, Gordinier M, Loercher A, Freedman RS: The role of cytocines in both the normal and malignant ovary. Endocr Rel Cancer, 6, 93-107, 1999.
20.Ben-Baruch A: Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: Reciprocal tumormicro-environment İnteractions. Breast Cancer Res, 5 (1): 31-36, 2003.
21.Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G: Serum IL-6, TNFα and CRP levels in greek colorectal cancer patients: prognostic implications, Prognostic implications. World J Gastroenterol, 11 (11): 1639-1643, 2005.
22.Nakagoe T, Tsuji T, Sawai T, Tanakaa K, Hidakaa S, Shibasakia S, Nanashimaa A, Ohbatakea M, Yamaguchia H, Yasutakea T, Sugawarab K, Inokuchib N: Increased serum levels of interleukin-6 in malnourished patients with colorectal cancer. Cancer Lett, 202, 109-115, 2003.
23.Ashisawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, Aoki T: Study of interleukın-6 in the spread of colorectal cancer: The diagnostic significance of IL-6. Acta Med Okayama, 60 (6): 325-330, 2006.
24.Shouda T, Hiraoka K, Komiya S, Hamada T, Zenmyo M, Iwasaki H, Isayama T, Fukushima T, Nagata K, Yoshimura A: Suppression of IL-6 production and roliferation by blocking STAT3 activation in malignant soft tissue tumor cells. Cancer Lett, 231, 176-184, 2004.
25.Schutter DH, Landuyt1 W, Verbeken E, Goethals L, Hermans R, Nuyts S: The prognostic value of the hypoxia markers CA IX and GLUT 1and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy. BMC Cancer, 5, 42, 2005.
26.Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid CA: Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res, 6, 3895-3903, 2000.
27.Giri D, Ozen M, Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol, 159, 6, 2001.
28.De Vita F, Romano C, Orditura M, Galizia G, Martinelli E, Lieto E, Catalano G: Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res, 21, 45-52, 2001.
29.Hussein M: Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. Oncologist, 7, 20-29, 2002.
30.Hussein M, Fikky AA, Bar IA, Attia O: Serum IL-6 and IL12 levels in breast cancer patients. The Egyp J Immunol, 11 (2): 165-170, 2004.